Other antiangiogenic agents including mAbs against VEGFR2, soluble VEGF receptors, and small-molecule inhibitors of the VEGF receptor tyrosine kinases (RTKs) were also found to inhibit tumor growth in xenografts and GEMMs [128]. Here, VEGFA is linked to neoplasm.